Kymera Therapeutics, Inc. (KYMR) insider trading.
In Q3 2026, insiders at Kymera Therapeutics, Inc. reported 36 non-derivative transactions on 8 Forms 3, 4 and 5: 0 open-market purchases and 32 sales worth $33.5M.
- Transactions
- 36
- Purchases (P)
- 0
- Sales (S)
- 32
- Net shares, P minus S
- -293,519
- Insiders
- 6
- Last filed
- 2026-09-04
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Booth Bruce | Director | 14 | 0 | 14 |
| Jacobs Bruce N. | Officer · Chief Financial Officer | 9 | 0 | 8 |
| Mainolfi Nello | Director, Officer · Chief Executive Officer | 8 | 0 | 6 |
| Adams Brian | Officer · Chief Legal Officer | 3 | 0 | 3 |
| Rooney Terence | Officer · Chief Medical Officer | 1 | 0 | 0 |
| Goodman Noah | Officer · Chief Business Officer | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-04 | Adams Brian | S (D) | 1,209 | $115.55 | 55,416 | Form 4 |
| 2026-09-04 | Adams Brian | S (D) | 3,025 | $116.81 | 52,391 | Form 4 |
| 2026-09-04 | Adams Brian | S (D) | 2,137 | $117.57 | 50,254 | Form 4 |
| 2026-07-27 | Rooney Terence | A (A) | 38,000 | $0 | 38,000 | Form 4 |
| 2026-07-07 | Mainolfi Nello | M (A) | 50,000 | $2.08 | 716,568 | Form 4 |
| 2026-07-07 | Mainolfi Nello | S (D) | 50,000 | $119 | 666,568 | Form 4 |
| 2026-07-01 | Mainolfi Nello | M (A) | 80,000 | $2.08 | 746,568 | Form 4 |
| 2026-07-01 | Mainolfi Nello | S (D) | 1,883 | $112.8 | 744,685 | Form 4 |
| 2026-07-01 | Mainolfi Nello | S (D) | 6,626 | $113.98 | 738,059 | Form 4 |
| 2026-07-01 | Mainolfi Nello | S (D) | 44,050 | $115.69 | 669,904 | Form 4 |
| 2026-07-01 | Mainolfi Nello | S (D) | 24,105 | $114.96 | 713,954 | Form 4 |
| 2026-07-01 | Mainolfi Nello | S (D) | 3,336 | $116.56 | 666,568 | Form 4 |
| 2026-07-01 | Goodman Noah | S (D) | 3,389 | $114.29 | 47,179 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 1,100 | $112.79 | 317,692 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 4,110 | $114.19 | 313,582 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 51,375 | $114.77 | 262,207 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 1,700 | $111.57 | 318,792 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 1,500 | $110.54 | 320,492 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | M (A) | 61,378 | $5.33 | 321,992 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 7,971 | $115.82 | 254,236 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 3,200 | $117.7 | 244,883 | Form 4 |
| 2026-06-30 | Jacobs Bruce N. | S (D) | 6,153 | $116.99 | 248,083 | Form 4 |
| 2026-06-29 | Booth Bruce | S (D) | 10,848 | $108.28 | 2,401,310 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 7,968 | $109.75 | 2,393,342 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 7,723 | $110.67 | 2,385,619 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 770 | $105.78 | 471,497 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 2,133 | $106.63 | 469,364 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 2,698 | $107.76 | 466,666 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 1,498 | $108.28 | 465,168 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 1,104 | $109.75 | 464,064 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 1,078 | $110.67 | 462,986 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 130 | $111.2 | 462,856 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 19,419 | $107.76 | 2,412,158 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 14,798 | $106.63 | 2,431,577 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 5,549 | $105.78 | 2,446,375 | Form 4/A |
| 2026-06-29 | Booth Bruce | S (D) | 934 | $111.2 | 2,384,685 | Form 4/A |
Transaction codes in this quarter
Get KYMR insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1815442&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · KYMR company page · Kymera Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Kymera Therapeutics, Inc. (KYMR)?
In Q3 2026, insiders at Kymera Therapeutics, Inc. reported 36 non-derivative transactions on 8 Forms 3, 4 and 5: 0 open-market purchases and 32 sales worth $33.5M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Kymera Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/kymr.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.